Request for Information: Opioids and People with Disabilities

A new Request for Information (RFI) from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) at ACL has been released today about opioids and people with disabilities.

NIDILRR is seeking input on the following areas related to the opioid public health emergency and people with disabilities. People with disabilities often experience chronic pain and, as a result, sometimes use opioids to address their pain. We are interested in understanding: 1) whether people with disabilities have been diagnosed and are being treated for an opioid use disorder, and 2) are clinics or community organizations observing a sizeable population of people with disabilities seeking treatment for opioid use disorder? If so, are current treatment strategies adequate and, if applicable, how is your organization adapting treatment strategies for people with disabilities?

NIDILRR is issuing this RFI to obtain input on the incidence of opioid use disorder among people with disabilities. This information will help NIDILRR determine what research might be needed to inform interventions and/or policies to mitigate the effects of opioid use disorder on people with disabilities. Topics of particular interest include opioid use among common subgroups of people with disabilities and their secondary conditions, and/or the effectiveness of existing or adapted treatment strategies for opioid use disorder among people with disabilities.

Please visit the link for more details about the RFI and the process to submit commentsComments must be submitted by February 20, 2018.

Within ACL, NIDILRR works to generate new knowledge and promote its effective use to improve the abilities of individuals with disabilities to perform activities of their choice in the community; and to expand society's capacity to provide full opportunities and accommodations for people with disabilities. NIDILRR conducts its work through grants that support research and development.

Additional Info Email: